






















































































































BASIC AND TRANSLATIONAL SCIENCE
Association of Polymorphisms in the Regulatory Region of
the Cyclophilin a Gene (PPIA) with Gene Expression and
HIV/AIDS Disease Progression
Paradise Madlala, PhD,* Ravesh Singh, PhD,* Ping An, MD, MPH,† Lise Werner, MSc,‡
Koleka Mlisana, MBChB, PhD,‡ Salim S. Abdool Karim, MBChB, PhD,‡ Cheryl A. Winkler, PhD,†
and Thumbi Ndung’u, BVM, PhD*§
Background: Human cyclophilin A (CypA) encoded by peptidyl
prolyl isomerase A gene (PPIA), enhances HIV-1 replication by
aiding capsid uncoating. The association of genetic variation in the
PPIA regulatory region with susceptibility to HIV-1 infection,
disease progression, and gene expression among black South
Africans at risk for infection or infected with HIV-1 is unknown.
Methods: We genotyped 539 participants from 2 longitudinal
study cohorts of black South Africans at high risk for infection or
infected with HIV-1 for PPIA regulatory single nucleotide poly-
morphisms by polymerase chain reaction–restriction fragment
length polymorphism.
Results: Minor allele (G) of SNP rs6850 (rs6850 G) significantly
associated with higher viral loads (mean 4.85 versus 4.46 log
copies/mL, P = 0.0006) and lower CD4+ T-cell counts (mean 506
versus 557 cells/mL, P = 0.0256) during the acute phase of infection
in the Centre for the AIDS Programme of Research in South Africa
(CAPRISA) 002 cohort. Consistently, rs6850 G significantly
associated with higher viral loads (mean 4.49 versus 4.01 log
copies/mL, P , 0.0001) and lower CD4+ T-cell counts (mean 442
versus 494 cells/mL, P = 0.0002) during the early chronic phase of
infection in the CAPRISA 002 cohort; rs6850 G further associated
significantly with rapid CD4+ T-cell decline in the CAPRISA 002
cohort (P = 0.0481) and Sinikithemba chronic infection cohort (P =
0.0156). Interestingly, rs6850 G significantly associated with
elevated CypA mRNA levels in HIV-1–positive individuals
(P = 0.0061).
Conclusions: These data suggest that rs6850 G enhances
HIV-1 replication through upregulation of CypA expression
following HIV-1 infection. The data support ongoing efforts to
develop anti–HIV-1 drugs that block interaction of HIV-1 and
cellular proteins.
Key Words: SNP, CypA, PPIA, HIV-1, mRNA expression
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INTRODUCTION
Human cyclophilin A (CypA) is a cellular cofactor for
HIV-1 replication.1–3 CypA, also known as peptidyl prolyl
isomerase A (PPIA), belongs to the cyclophilin family,
members of which all possess peptidyl prolyl cis/trans
isomerase activity (by convention, the protein is referred to as
CypA and the gene as PPIA). Peptidyl prolyl cis/trans
isomerases catalyze the cis/trans isomerization of prolyl peptide
bonds and are involved in protein folding.4 After viral entry into
the cytoplasm, CypA is believed to play a role in uncoating of
the viral core based on its peptidyl propyl isomerase activity.
HIV-1 capsid (CA) directly interacts with the active sites of
CypA through a prolyl peptide bond located in a proline-rich
loop between the fourth and fifth helix loops and this leads to
the incorporation of CypA into the HIV-1 virion capsid.5,6
Disruption of the interaction between CypA and HIV-1,
either by HIV-1 Gag mutations or by cyclosporine A, an
immunosuppressive drug that prevents HIV-1 Gag binding to
CypA, leads to attenuation of HIV-1 infectivity.3,7 HIV-1
replication was significantly inhibited in CypA-null human
CD4+ T cells, in which PPIA was deleted through homologous
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recombination. CypA is therefore an important host factor
required for efficient HIV-1 infection.8 CypA increases viral
infectivity by facilitating proper uncoating. In addition, binding
of CypA to capsid protects HIV-1 from an unknown restriction
factor in humans.9
Although different groups have identified single nucleo-
tide polymorphisms (SNPs) in the regulatory region of PPIA that
affect HIV-1 clinical outcomes in different populations,10–12 the
data are inconsistent and populations studied bear less burden of
HIV-1/AIDS compared with the situation in sub-Saharan
Africa.13 Bleiber et al11 demonstrated an association of
the minor allele (G) of SNP rs6850 (referred to as rs6850 G
henceforth) with rapid disease progression in a Swiss cohort.
Subsequently, An et al10 reported higher frequency of rs6850 G
among HIV-1 seroconverters (SC) compared with the high-risk
seronegative (SN) group suggesting an association with
increased susceptibility to HIV-1 infection. Although there was
a nonsignificant association of rs6850 G with CD4 cell depletion
in African Americans, no evidence of association was observed
in European Americans. In contrary, rs6850 G was significantly
increased in high-risk seronegative group of the Amsterdam
Cohort Studies (ACS) compared with HIV-1–infected group
suggesting that rs6850 G may be associated with reduced
susceptibility to HIV-1 infection in participants of the ACS.12
An et al10 found rs8177826 G, which is in perfect linkage
disequilibrium with SNP rs8177830, to be associated with
accelerated progression to AIDS in African Americans. Consis-
tently, Rits et al12 demonstrated that rs8177826 G was associated
with accelerated progression as assessed by viral load threshold.
The present study was undertaken in an attempt to shed
more light on the role of PPIA promoter polymorphisms on
HIV-1 pathogenesis in an African population. Two SNPs
rs8177830 and rs6850 were selected because previous studies,
conducted in American and European cohorts had reported the
association of rs8177830 with rapid disease progression and
inconsistent findings were reported regarding the association of
rs6850 with susceptibility to HIV-1 acquisition. Specifically,
we wanted to address the role of PPIA polymorphisms in
a sub-Saharan population in which HIV-1 prevalence is high
because there is paucity of data for the role of human genetic
variation in HIV/AIDS pathogenesis for this population and
because novel therapeutic interventions would be most relevant
for this setting. Furthermore, we sought to explore the possible
mechanisms by which PPIA polymorphisms may affect HIV-1
pathogenesis. We focused on PPIA expression levels because
of previous in vitro data suggesting that CypA levels are
largely responsible for differences in HIV replication between
CEM-GXR and Jurkat cells.14 We thus investigated the
association of 2 SNPs, rs8177830 and rs6850, with suscepti-
bility to HIV-1 infection, disease progression, and CypA
mRNA levels in a population of black South Africans that
has a high burden of HIV-1 infection.
METHODS
Study Participants
Participants in this study were from 2 study cohorts of
a black South African population in KwaZulu-Natal,
Durban, South Africa. The first cohort was the Centre for
the AIDS Programme of Research in South Africa
(CAPRISA) 002 cohort.15 The CAPRISA 002 cohort is
an ongoing observational natural history study of HIV-1
subtype C infection established in Durban, South Africa in
2004. HIV-1–negative women (n = 245) at high risk for
HIV-1 infection were enrolled into phase I of the study.
Participants in this cohort were screened monthly for recent
HIV-1 infection by 2 rapid HIV-1 antibody tests, Deter-
mine (Abbott Laboratories, Tokyo, Japan) and Capillus
(Trinity Biotech, Jamestown, NY). HIV-1 antibody-negative
samples were tested for HIV-1 RNA in batches of 10 plasma
samples per pool using the Ampliscreen v1.5 assay (Roche
Diagnostics, Rotkreuz, Switzerland), which has a detection
limit of 10 copies per milliliter. Samples that tested positive in
pooled plasma were individually tested by quantitative RNA
(Amplicor v2.0, Roche Diagnostics) and HIV enzyme immu-
noassay (BEP 2000; Dade Behring, Marburg, Germany) to
identify the HIV-1–positive sample. CD4+ T-cell counts
were determined by a 4-parameter FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ).
Twenty-eight participants seroconverted with acute HIV-1
infection were enrolled into phase II of the CAPRISA 002
study on the basis of a reactive HIV antibody test within 5
months of previously negative results or positive HIV RNA
polymerase chain reaction (PCR) in the absence of anti-
bodies. A further 34 acutely HIV-1 subtype C infected
participants from other the seroincidence studies of black
South Africans from KwaZulu-Natal were also enrolled into
phase II if they met the above criteria for inclusion in the
acute infection phase, therefore establishing a cohort of 62
HIV seroconverters, all antiretroviral naive. For the pur-
poses of this study, samples from 168 HIV SN participants
and 47 participants with recent HIV infection (SC) were
available and used for analysis. Date of infection was
estimated by taking the midpoint between the last HIV
antibody-negative result and the first HIV antibody-positive
result or 14 days before the first positive HIV RNA PCR
assay result for those identified as antibody negative but
HIV RNA positive. Participants in phase II were intensively
followed-up by monitoring them weekly for 3 weeks,
fortnightly for 2 months, then monthly for 9 months, and
quarterly thereafter.
The second study cohort was the Sinikithemba cohort
comprising of 450 antiretroviral naïve, subtype C chroni-
cally infected black South Africans enrolled from McCord
Hospital in KwaZulu-Natal, Durban, South Africa from
August 2003 to 2008 and followed-up longitudinally.16,17
The estimated time of infection for these participants is
unknown. Samples from 324 participants were available for
the present study. Sociodemographic characteristics, plasma
viral load, and CD4+ T-cell count measurements were
obtained at baseline (Table 1). CD4+ T-cell counts and viral
loads were measured every 3 and 6 months, respectively,
from enrollment. Viral loads were determined using the
automated Cobas Amplicor HIV-1 Monitor test (version 1.5;
Roche Diagnostics). CD4+ T cells were enumerated using
the Multitest kit (CD4/CD3/CD8/CD45) on a FACSCalibur
flow cytometer (Becton Dickinson).
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Peripheral Blood Mononuclear Cells
Sample Processing
Peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll-Histopaque (Sigma) density gradient cen-
trifugation from blood within 6 hours of phlebotomy and
frozen in liquid nitrogen until use. Ethical approval was
obtained from the Biomedical Research Ethics Committee of
the University of KwaZulu-Natal. All participants provided
written informed consent.
Genotyping for Regulatory SNPs (rs6850 and
rs8177830) in the PPIA
SNPs (rs8177830 and rs6850) were first genotyped in
the aforementioned available DNA samples from CAPRISA
002 cohort by restriction fragment length polymorphism
assay as previously reported.10 Briefly, DNA samples were
amplified by PCR using Taq DNA polymerase (Invitrogen,
Carlsbad, CA) in the presence of 1.25 mM MgCl2
with the following primer set: forward primer, CypAex-1s:
59-AAGTCGCAGACCCGATTG-39 and reverse primer,
CypA-1a: 59-ACTTTCTGGGCCCCATTC-39. Subse-
quently, PCR products were subjected to a restriction digest
with RsaI and HaeIII (New England Biolabs, Ipswich, MA)
overnight at 37°C and analyzed on a 4% agarose gel, to
detect polymorphisms.
CypA mRNA Expression Analysis and In Vitro
Replication Assay
PBMCs were isolated from a total of 28 SN and 28 SC
participants with known genotypes for SNP rs6850 from the
CAPRISA 002 cohort. There were at least 2 study time points
available for each of the participants in the primary HIV-1
infection phase and a total of 75 separate samples were
analyzed for this group. Thirteen matched samples were
included in this analysis.
RNA Isolation and Analysis
For all samples, RNA was extracted immediately after
thawing and counting of PBMCs without in vitro stimulation.
RNA was extracted from 2 · 106 PBMCs using the RNeasy
Mini Kit (Qiagen, Hilden, Germany). The total RNA
concentration was quantified and samples were used only if
the OD260/OD280 ratio was 1.90 or greater. All RNA samples
were DNAse treated. Approximately 1 mg of total RNA from
each sample was reversed transcribed using the iScript cDNA
synthesis kit (Biorad Laboratories, Inc, Berkeley, CA).
Real-Time PCR RNA Quantitation
CypA mRNA levels were analyzed by SYBR green
qPCR using the LightCycler 480 (Roche). Each PCR reaction
consisted of 3 mmol/mL MgCl2, the respective primers at 0.5
pmol/mL, 1 mL Fast Start SYBR Green I (Roche), 1 mg cDNA
and water to make the total reaction volume to 10 mL. CypA
cDNA was detected using the following primer set, CypA-F:
59-GTCAACCCCACCGTGTTCTTC-39 and CypA-R:
59-TTTCTGCTGTCTTTGGGACCTTG-39. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) determined to be the
most suitable reference gene based on PCR efficiency was used
to correct for differences in the cDNA input, GAPDH cDNA
was detected using the following primer set: GAPDH-F:
59-GTCAACCCCACCGTGTTCTTC-39 and GAPDH-R:
59-TTTCTGCTGTCTTTGGGACCTTG-39. SYBR green
qPCR was performed using the following program on the
LightCycler 480: (1) preincubation: 95°C for 5 minutes; (2)
amplification: 45 cycles of 95°C for 15 seconds, 60°C for 15
seconds, and 72°C for 15 seconds; (3) melting curve: 95°C for
5 seconds, 65°C for 1 minute, and 97°C for 0 seconds with
a temperature transition rate of 0.11°C/sec. To confirm
amplification specificity, the PCR products were subjected to
a melting curve analysis. Serial dilutions of cDNA from total
RNA were performed for each target gene to create standard
curves for quantitative analysis.
HIV-1 In Vitro Replication Assay
HIV-1 replication capacity was assessed in PBMCs
isolated from 20 healthy HIV uninfected individuals with known
genotypes for SNP rs6850. PBMCs were isolated as aforemen-
tioned. PBMCs (2 · 106/mL) were stimulated for 48 hours in
R10 buffer [Roswell Park Memorial Institute (RPMI)-1640
medium (Grand Island, NY) supplemented with 10% fetal
calf serum (Hyclone Inc., Logan), gentamicin (Gibco-Brl,
Gaithersburg, MD) (100 mg/mL)] containing 5 mg/mL phyto-
hemagglutinin (PHA) (Roche, Indianapolis, IN) and interleukin-
2 (IL-2) (Roche). Following stimulation with PHA/IL-2, cells
were washed with R10 buffer and then infected with HIV IIIB
(NIH AIDS Reagent Repository) at 0.1 MOI by spinoculation (2
hours, 2500 RPMs, 37°C). Infection was performed in a 24-well
plate. Virus was subsequently removed by washing the cells,
TABLE 1. Baseline Characteristics of the CAPRISA 002 Acute Infection Cohort and Sinikithemba Chronic Infection Cohort
PPIA SNP rs6850 in CAPRISA 002 Acute Infection
PPIA SNP rs6850 in Sinikithemba Chronic Infection
Cohort
Characteristics* AA (n = 23) AG (n = 18) GG (n = 6) MAF H-W AA (n = 146) AG (n = 124) GG (n = 54) MFA H-W
Age, yrs, median (IQR) 25 (22–37) 25 (19–31) 23 (21–25) 0.35 0.55 30 (27–34) 29 (25–34) 31 (26–38) 0.36 0.003
Sex, female (%) 23 (100) 18 (100) 6 (100) 115 (78.8) 98 (79.0) 43 (79.6)
CD4 cells/mL, median
(IQR)
535 (420–877) 877 (671–973) 574 (518–695) 327 (209–459 394 (256–518) 357 (281–579)
Log viral loads, median
(IQR)
4.6 (3.8–5.3) 4.9 (4.5–5.8) 5.0 (4.5–5.6) 4.8 (4.0–5.3) 4.8 (4.0–5.4) 4.6 (3.7–5.2)
*Age of participants is at recruitment into the study, viral and CD4 measurements are at time of HIV diagnosis.
n, number of individuals; MFA, minor allele frequency; H-W, Hardy–Weinberg; IQR, interquartile range.
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followed by cell culture for 10 days. CypA mRNA expression
levels were analyzed by real-time PCR in these cultured cells.
Cell culture supernatants from day 2, 7, and 10 were harvested
and analyzed by p24 antigen capture enzyme-linked immuno-
sorbent assay (Vironostika, Biomérieux).
Statistical Analysis
The difference in allele frequency distribution between
the SN and SC group was determined by Fisher exact test for
SNPs rs8177830 and rs6850 to test the null hypothesis that
allele frequencies were the same between individuals carrying
the wild-type and mutant genotypes.
The association of SNP rs6850 with CD4+ T-cell counts
and HIV-1 viral loads was determined using a generalized
estimating equation model18 taking into account longitudinal
measures for each participant. Viral loads were log-
transformed and the square root of CD4+ T-cell counts was
used to normalize their measurements.
In the CAPRISA 002 cohort, Kaplan–Meier survival
curves and proportional hazards models were used to assess
the effect of SNP rs6850 on time to HIV-1 acquisition after
enrollment and on CD4+ T-cell decline to less than 350 cells
per microliter (CD4,350). A linear mixed model was used to
estimate the rate of CD4+ T-cell decline in participants
harboring the wild-type versus mutant genotypes from the
Sinikithemba cohort.
CypA mRNA expression levels were compared
between SN and SC groups using nonparametric statistical
analysis, and Pearson correlation. Values were expressed as
median values. Differences between the groups were evalu-
ated using Dunn multiple comparison test or the Mann–
Whitney U test. The software used for the analysis was
GraphPad prism version 5 and SAS version 9.3 (SAS Institute
Inc., Cary). A result was considered significant if the P-value
was ,0.05.
RESULTS
In the present study, we investigated the frequency of
rs8177830 located and SNPs rs6850 in the regulatory region of
PPIA in a total of 539 participants from 2 black South African
HIV-1 cohorts; 168 SN and 47 SC participants were from the
CAPRISA 002 cohort and 324 participants from the Siniki-
themba chronic HIV-1 infection cohort (Fig. 1). rs8177830 G
was infrequent (minor allele frequency = 0.01) in the
CAPRISA 002 cohort and therefore SNP rs8177830 was
excluded from any further analysis and genotyping in the
Sinikithemba chronic HIV-1 infection cohort.
SNP rs6850 has No Direct Association With
Susceptibility to HIV-1 Acquisition
The study design of the CAPRISA 002 cohort in which
participants at high risk for HIV-1 infection were enrolled
while HIV-1 negative and followed longitudinally for 2 years,
allowed us to study the association of SNP rs6850 with
FIGURE 1. Design of South African HIV-1 cohorts used in this study and the number of participants genotyped from each group.
*Quarterly follow-up is 3 monthly viral loads and 6 monthly CD4 cell counts measurements.
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susceptibility to HIV-1 infection. There was no distortion in
SNP rs6850 distribution between SN and SC participants
(relative hazard, 1.57; 95% CI: 0.64 to 3.62, P = 0.3067)
(Table 2). These data suggest that SNP rs6850 may not
influence HIV-1 acquisition at least in a population of black
South Africans.
TABLE 2. Effect of PPIA SNP rs6850 on HIV-1 Acquisition Risk
PPIA SNP Risk Group n
Genotype SP Versus SN
No. Carriers (Frequency) Hazard Ratio (95% CI)
PAA AG GG AA Versus AG/GG
rs6850 SN 168 79 (0.42) 76 (0.41) 13 (0.07)
SC 47 23 (0.49) 18 (0.38) 6 (0.13) 1.57 (0.64 to 3.62) 0.31
CI, confidence interval; n, number of individuals.
FIGURE 2. Association of SNP rs6850 with clinical outcomes during primary HIV-1 infection in the CAPRISA 002 cohort. The
horizontal line in the middle of the whiskers plot denotes the median value. The differences between groups were evaluated using
generalized estimating equation. P , 0.05 denotes statistical significance. A and B, association of rs6850 G with lower CD4+ T-cell
counts and higher viral loads, respectively, during the acute phase of infection. C and D, association of rs6850 G with lower CD4+
T-cell counts and higher viral loads, respectively, during the early chronic phase of infection.
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Influence of SNP rs6850 on CD4+ T-cell
Counts and Viral Loads
A dominant model analysis using generalized estimating
equation was used to compare CD4+ T-cell counts and viral
loads between individuals who carried the wild-type genotype
(rs6850AA) and those carrying mutant genotypes (rs6850AG/
GG) in the CAPRISA 002 cohort. Consistent with the ex vivo
data reported by Bleiber et al,11 the rs6850 G was significantly
associated with lower CD4+ T-cell counts (mean 506 versus
557 cells/mL, P = 0.026) (Fig. 2A) and higher viral loads (mean
4.85 versus 4.46 log copies/mL, P , 0.001) (Fig. 2B) during
the acute phase of infection (0–3 months). Interestingly, rs6850
G was also significantly associated with lower CD4+ T-cell
counts (mean 442 versus 494 cells/mL, P = 0.001) (Fig. 2C)
and higher viral loads (mean 4.49 versus 4.01 log copies/mL,
P , 0.001) (Fig. 2D) during early chronic phase of infection
(3–12 months). Given that the time of infection was known and
specific time points were analyzed for black South Africans in
the CAPRISA 002 cohort, our study suggests that rs6850 G
may be associated with enhanced HIV-1 replication in vivo.
Effect of SNP rs6850 on Disease Progression
Next, we examined the effect of rs6850 G on disease
progression as reflected by time to CD4 ,350 cells per
microliter in SC from the CAPRISA 002 cohort. The rs6850
G was marginally associated with rapid CD4+ T-cell decline
(relative hazard, 3.18; 95% CI: 1.01 to 10.04, P = 0.048)
(Fig. 3A). This borderline association could be due to a small
sample size (only 47 SC from the CAPRISA 002 cohort).
Samples from 324 black South Africans in the Siniki-
themba chronic HIV-1 infection cohort were available to study
the association of SNP rs6850 with the rate of CD4+ T-cell
decline during follow-up since enrolment. Interestingly, rs6850
G was significantly associated with rapid CD4+ T-cell decline
in the Sinikithemba chronic HIV-1 infection cohort during
follow-up (P = 0.016) (Fig. 3B). Taken together, the data from
the 2 black South African HIV-1 infection cohorts suggest that
rs6850 G may be associated with rapid HIV-1 disease
progression among black South Africans.
Effect of rs6850 G on CypA Expression Levels
In Vivo
As rs6850 SNP is located in the upstream regulatory
region of the PPIA gene, we reasoned that it may regulate the
transcription levels of the gene. Therefore, we examined the
association of rs6850 G with CypA mRNA expression levels
in vivo. We performed quantitative reverse transcriptase PCR
to measure CypA mRNA levels in PBMCs of 28 SN and 28
SC participants. There were no differences in CypA mRNA
expression levels between participants carrying rs6850AA
and rs6850AG/GG in the SN group (Fig. 4A). These data
suggest that CypA is not differentially expressed according to
this allele in a general population. However, rs6850 G was
significantly associated with elevated CypA mRNA expres-
sion levels following HIV-1 infection (P = 0.006) (Fig. 4B).
The data from Figure 4B suggest a plausible mechanism
where HIV-1 infection modulates CypA mRNA expression
levels in the presence of regulatory region SNP, rs8650 G.
Taken together, the expression data suggest that rs6850 G
may not be associated with susceptibility to HIV-1 infection
but with enhanced HIV-1 replication in vivo.
Effect of rs6850 G on CypA Expression Levels
and HIV-1 Replication Ex Vivo
Last, we assessed HIV-1 replication capacity in PHA/
IL-2 stimulated PBMCs from 20 SN participants with known
SNP rs6850 genotypes. CypA mRNA levels were measured
in PHA/IL-2 stimulated PBMCs by performing quantitative
FIGURE 3. The association of SNP rs6850 with CD4+ T-cell decline. A, Kaplan–Meier survival curve analysis of SNP rs6850 for
CD4+ T decline in the CAPRISA 002 cohort. B, Rates of CD4+ T-cell decline stratified by genotypes for SNP rs6850. CD4+ T-cell
decline in participants harboring the wild-type genotype (rs6850AA) is shown by a black curve, whereas the red curve represents
CD4+ T-cell decline in participants harboring mutant genotypes (rs6850AG/GG).
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reverse transcriptase PCR before and after HIV-1 infection.
There were no differences in CypA mRNA expression levels
between PBMCs harboring 6850AA and 6850AG/GG before
HIV-1 infection, whereas rs6850 G variant was associated
with higher CypA mRNA expression levels at day 7 and day
10 postinfection (P = 0.053 and P = 0.045, respectively; Fig.
4C). Although there was a borderline association of rs6850
with higher CypA mRNA expression after in vitro HIV-1
infection of PBMCs probably because of short infection
period (up to 10 days), these data further suggest that CypA
may be modulated by HIV-1 infection among individuals
harboring rs6850 SNP. These data suggest that rs6850 may be
associated with enhanced HIV-1 replication and/or disease
progression but susceptibility to HIV-1 acquisition.
In an attempt to generate further evidence for the possible
role of the rs6850 G polymorphism in promoting HIV-1
replication, we analyzed the replicative capacity of HIV-1 in
PHA/IL-2 stimulated PBMCs by p24 antigen enzyme-linked
immunosorbent assay measurements. There was nonsignificant
trend of association of rs6850 G with higher p24 production
levels (Fig. 4D). Lack of significant difference in p24 pro-
duction could be attributed to a shorter inoculation period of
PBMCs with the virus consistent with the data of the previous
study.12 Taken together, these data suggest that rs6850 G
promotes efficient HIV-1 replication through elevated PPIA
expression levels in the context of HIV-1 infection.
DISCUSSION
The role of CypA in promoting HIV-1 replication was
initially established through extensive in vitro experi-
ments.2,3,7,8 Subsequent studies investigated the association
FIGURE 4. Expression of CypA mRNA levels in PBMCs obtained from participants in the CAPRISA 002 cohort. Data are repre-
sented as the normalized ratio of CypA to GAPDH. The horizontal line in the middle of the points denotes the median value. The
differences between groups were evaluated using Mann–Whitney U test. P , 0.05 denotes statistical significance. A, CypA mRNA
expression levels in PBMCs from nonseroconverters. B, CypA mRNA expression levels in PBMCs from primary infected partic-
ipants. C, CypA mRNA expression levels in PHA/IL2 stimulated PBMCs obtained from seronegative participants with known
genotypes and subsequently infected with HIV IIIB. D, HIV-1 replication capacity in PBMCs with known genotypes as measured by
p24 production.
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of CypA genetic variation with HIV-1 disease outcome in
different population groups, as one powerful approach to
confirm the importance of CypA in vivo.10–12 rs6850 G in the
regulatory region of PPIA was associated with increased
susceptibility to HIV-1 acquisition in European Americans10
while it was shown to be associated with protection against
HIV-1 infection in the ACS.12 Given the discrepancies in the
data obtained from previous studies, we wanted to elucidate
the role of CypA genetic variation in HIV-1 acquisition and
disease progression in an African setting with high HIV
prevalence. Contrary to the previous studies,10,12 there was no
evidence of association of rs6850 G with susceptibility to
HIV-1 infection in our cohort. One possible reason for the
discrepancies in results between studies is that allele frequen-
cies vary among potential disease-influencing gene variants
according to ethnic groups and geographically separated
populations.19 We speculate that there may be other modify-
ing biological factors that affect the interaction of this SNP
with HIV-1 following exposure to the virus thus resulting in
divergent data depending on cohort or study population
analyzed. The presence of another SNP that may be in
linkage disequilibrium with SNP rs6850 could not be
excluded from the reported possible influence of rs6850 G
on susceptibility to HIV-1 infection. Therefore, the role of
rs6850 G in susceptibility to HIV-1 infection remains
inconclusive and warrants further investigation. Although
SNP rs8177826, a proxy for SNP rs8177830, was associated
with rapid progression to AIDS in the American population10
and among European drug users,12 SNP rs8177830 was very
rare in the South African study population and therefore could
not be analyzed for association with HIV-1 infection outcome
in the present study.
Our data demonstrate that rs6850 G was significantly
associated with lower CD4+ T-cell counts and higher viral
loads as early as 3 months post–HIV-1 infection, confirming
the importance of CypA in promoting HIV-1 replication as was
suggested by in vitro data.2,3,7,8 Interestingly, rs6850 was further
associated with rapid CD4+ T-cell decline in both black South
African cohorts. Although there was no clear association of
SNP rs6850 with CD4+ T-cell decline in the African or
European American populations,10 Bleiber et al11 and our data
clearly demonstrate the association of rs6850 G with rapid
CD4+ decline. Taken together, our data suggest an association
of CypA genetic variation with HIV-1 disease outcome.
Consistent with the previous study,12 SNP rs6850 was
not associated with CypA expression in a general population
of SN. However, our results demonstrate an increase in CypA
mRNA expression levels in PBMCs isolated from SC
participants carrying rs6850AG/GG compared with PBMCs
from rs6850AA carriers. These data suggest that rs6850 G
enhances HIV-1 replication by upregulating the CypA
expression levels following HIV-1 infection. Following ex
vivo HIV-1 infection of PBMCs obtained from SN partic-
ipants with known SNP rs6850 genotypes, CypA mRNA
levels increased in PBMCs obtained from rs6850AG/GG
compared with rs6850AA carriers. Consistent with the in vivo
data, rs6850 G supported high ex vivo viral replication
compared with rs6850A as was reflected by p24 production.
In light of the Gel Shift assay from An et al,10 it can be
postulated that rs6850, which is in the regulatory region of
PPIA, enhances the interaction of HIV-1 capsid (CA) with
CypA leading to the incorporation of more CypA into the
HIV-1 virion capsid. Increased CypA mRNA levels in
rs6850AG/GG PBMCs following ex vivo HIV-1 infection
may suggest an unknown mechanism where HIV-1 infection
dysregulate CypA mRNA expression. Taken together, our
results suggests that rs6850 G is associated with differential
gene expression in the context of HIV infection, enhanced
HIV-1 replication, and rapid CD4+ T-cell decline among
black South Africans.
The major limitation of the present study is the small
sample size especially for the cohort with known time of
infection. It would be informative to study these polymor-
phisms in a larger sub-Saharan African cohort with known
time of HIV-1 infection. It is worth pointing out that SNP
rs6850 was not detected as having a significant effect on viral
set point in genome-wide association studies,20,21 which could
imply a more modest effect on HIV-1 clinical outcomes
compared with the HLA locus or possibly because of
population/ethnic differences in allele frequencies because
the genome-wide association studies were performed in non-
African populations, with the exception of one study that
found no association between genetic polymorphisms and
HIV-1 susceptibility.22 Other reasons could be cohort design
and outcome measures used, Pereyra et al investigated genetic
variants associated with elite HIV-1 control20 and Fellay
et al21 studied genetic association with viral load set point.
In conclusion, our study demonstrates that the rs6850 G
variant in the PPIA gene is associated with enhanced HIV-1
replication in 2 black South African HIV-1 cohorts. These
findings are consistent with a crucial role for CypA in
productive HIV-1 infection and lend support to ongoing
efforts to develop antiretroviral drugs that can block the
interaction between HIV-1 proteins and cellular proteins to
disrupt the virus life cycle.
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